<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Vote</th>
</tr>
</thead>
</table>
### WMLPL-B

**Internal request:** Add bortezomib/dexamethasone to the list of options for primary and salvage therapy

In the salvage setting, addition of dexamethasone to bortezomib in patients with relapsed and/or refractory myeloma who had suboptimal responses to bortezomib alone was associated with improvement in responses. Therefore, this regimen is included in the WM guidelines as a category 2A recommendation in the salvage setting. Bortezomib-containing regimens have shown to be active as primary therapy for WM. Therefore, bortezomib/dexamethasone was included as a category 2A option in the primary setting.


| 13 | 0 | 0 |

### WMLPL-B

**Internal request:** Add fludarabine/cyclophosphamide/rituximab regimen (FCR) to the list of options for primary and salvage therapy

Results of a multicenter, prospective clinical trial demonstrate that FCR produces rapid responses with high rates of CR and VGPR in patients with WM. This has been added as a category 2A recommendation under primary and salvage therapy options.


| 13 | 0 | 0 |
| WMLPL-B | Internal request: Include ofatumumab as a salvage therapy option for rituximab-intolerant individuals | A phase II study demonstrated that ofatumumab could be successfully administered in patients with WM who were intolerant to rituximab. Ofatumumab has been added to the guidelines as a category 2A recommendation as salvage therapy for patients who are intolerant to rituximab. | Furman RR, Eradat H, Switzky JC, et al. A phase II trial of ofatumumab in subjects with Waldenstrom's macroglobulinemia. ASH Annual Meeting Abstracts 2010;116:1795-. Available at [http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/1795](http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/1795) | 13 | 0 | 0 |